相关实验视频

Updated: May 5, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

患有费城染色体阴性髓增殖新生瘤的患者的二次固体癌症:一个多中心研究

Fehmi Hindilerden¹, Özge Nuran Akay¹, Elif Aksoy¹

¹University of Health Sciences Türkiye, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye

Turkish journal of haematology : official journal of Turkish Society of Haematology

|August 8, 2024

概括

二次固体癌症 (SSCs) 影响6.6%的费城染色体阴性骨髓扩散性瘤 (Ph-MPN) 患者. 动脉血栓是危险因素,而基于干扰素的治疗可以防止SSCs.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床研究临床研究

背景情况:

费城染色体阴性骨髓扩散性新生瘤 (Ph-MPNs) 是一组血液癌症.
二次固体癌症 (SSCs) 可以在患有MPN的患者中发展,影响他们的预后.
了解Ph-MPN患者SSC的风险因素和保护因素至关重要.

研究的目的:

研究土耳其Ph-MPN患者中SSC的发生和特征.
识别与SSC发展相关的风险因素,包括细胞减少疗法.
评估SSC对患者存活率的影响.

主要方法:

在1995年至2022年期间诊断的1013名Ph-MPN患者的回顾性分析.
收集有关人口统计,临床参数,SSC发展,治疗暴露和生存的数据.
使用IBM SPSS统计的统计分析 26.0.0.

主要成果:

在Ph-MPN患者中,6.6%患有SSC,主要是癌瘤.
诊断时的年龄较大和男性性别与增加的SSC风险有关.
动脉血栓形成是一个独立的风险因素,而基于干扰素 (IFN) 的治疗是保护性的.
总体存活率没有显著差异,除了SSCs的多细胞血病患者.

结论:

动脉血栓症增加了Ph-MPN患者的SSC风险;基于IFN的治疗可能会提供保护.
建议在患有动脉栓塞的Ph-MPN患者中对SSC进行查.
需要进一步的研究来了解机制并优化管理.

关键词:

费城染色体阴性骨髓扩散性瘤二次固体癌症二次固体癌症细胞减少疗法治疗.干扰素干扰素干扰素

更多相关视频

Analysis of Side Population in Solid Tumor Cell Lines

Analysis of Side Population in Solid Tumor Cell Lines

Published on: February 23, 2021

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...